#### INTERLEUKIN GENETICS INC

Form 4

August 02, 2016

# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

burden hours per response...

**OMB APPROVAL** 

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* BAY CITY CAPITAL LLC

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

INTERLEUKIN GENETICS INC

(Check all applicable)

[ILIU]

(Middle)

(Last) (First) 3. Date of Earliest Transaction

Director Officer (give title \_X\_\_ 10% Owner \_\_Other (specify

750 BATTERY STREET, SUITE

(Street)

400

4. If Amendment, Date Original

Applicable Line)

below)

Filed(Month/Day/Year)

(Month/Day/Year)

07/29/2016

Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Person

SAN FRANCISCO, CA 94111

| (City)                               | (State)                              | (Zip) Ta  | ble I - Non                            | -Derivative Sec                                    | urities | s Acquired   | , Disposed of, or  | Beneficially   | Owned   |
|--------------------------------------|--------------------------------------|---|--|--|---------|--------------|--|--|---|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transactic<br>Code<br>(Instr. 8) | 4. Securities AdorDisposed of (D) (Instr. 3, 4 and | )       | d (A) or     | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
| Common<br>Stock                      | 07/29/2016                           |   | P                                      | 29,616,700   | A       | \$<br>0.0994 | 75,800,716   | I  | See footnotes (1) (2)   |
| Common<br>Stock                      | 07/29/2016                           |   | P                                      | 564,386  | A       | \$<br>0.0994 | 1,444,485  | I  | See footnotes (1) (3)   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control

(9-02)

# Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

#### number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactio<br>Code<br>(Instr. 8) | 5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amou<br>Underlying Securi<br>(Instr. 3 and 4) |                    |
|---|---|---|---|--|---|--|--------------------|--|--------------------|
|   |   |   |   | Code V                                 | (A) (D)   | Date<br>Exercisable                                      | Expiration<br>Date | Title  | Amo<br>Num<br>Shar |
| Common<br>Stock<br>Warrant<br>(right to<br>buy)     | \$ 0.0994   | 07/29/2016                              |   | P                                      | 29,616,700  | 07/29/2016   | 07/29/2023         | Common<br>Stock  | 29,                |
| Common<br>Stock<br>Warrant<br>(right to<br>buy)     | \$ 0.0994   | 07/29/2016                              |   | P                                      | 564,386   | 07/29/2016   | 07/29/2023         | Common<br>Stock  | 50                 |

# **Reporting Owners**

|  | Relationships |              |         |       |  |
|--|---------------|--------------|---------|-------|--|
| Reporting Owner Name / Address   | Director      | 10%<br>Owner | Officer | Other |  |
| BAY CITY CAPITAL LLC<br>750 BATTERY STREET, SUITE 400<br>SAN FRANCISCO, CA 94111                       |               | X            |         |       |  |
| Bay City Capital Fund V, L.P.<br>750 BATTERY STREET, SUITE 400<br>SAN FRANCISCO, CA 94111              |               | X            |         |       |  |
| Bay City Capital Fund V Co-Investment Fund, L.P. 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111 |               | X            |         |       |  |
| Bay City Capital Management V LLC<br>750 BATTERY STREET, SUITE 400<br>SAN FRANCISCO, CA 94111          |               | X            |         |       |  |
| Signatures   |               |              |         |       |  |

| /s/ Michael Lawhead, | 08/02/2016 |
|----------------------|------------|
| attorney-in-fact     | 06/02/2010 |

Date \*\*Signature of Reporting Person

Reporting Owners 2

### Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V"), are deemed to be a "group" for the purpose of Section
- (1) 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V.
- (2) Represent securities held by Fund V, including indirect interests of Management V. Management V disclaims beneficial ownership with respect to these securities, except to the extent of its pecuniary interest therein.
- (3) Represent securities held by Co-Investment V, including indirect interests of Management V. Management V disclaims beneficial ownership with respect to these securities, except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.